These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 32660401)

  • 1. COVID-19 Outbreak and Emerging Management through Pharmaceutical Therapeutic Strategy.
    Rahman MH; Akter R; Behl T; Chowdhury MAR; Mohammed M; Bulbul IJ; Elshenawy SE; Kamal MA
    Curr Pharm Des; 2020; 26(41):5224-5240. PubMed ID: 32660401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody Therapy for COVID-19: Categories, Pros, and Cons.
    Zare Marzouni H; Rahbar M; Seddighi N; Nabizadeh M; Meidaninikjeh S; Sabouni N
    Viral Immunol; 2022 Oct; 35(8):517-528. PubMed ID: 36201297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of potential therapeutic candidates for the COVID-19 crisis.
    Zhang J; Xie B; Hashimoto K
    Brain Behav Immun; 2020 Jul; 87():59-73. PubMed ID: 32334062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
    Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T
    BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021).
    Panovska-Stavridis I; Ridova N; Stojanoska T; Demiri I; Stevanovic M; Stojanovska S; Ristevska T; Dimkovski A; Filipce V; Dimovski A; Grozdanova A
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2021 Apr; 42(1):5-18. PubMed ID: 33894123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments.
    Canedo-Marroquín G; Saavedra F; Andrade CA; Berrios RV; Rodríguez-Guilarte L; Opazo MC; Riedel CA; Kalergis AM
    Front Immunol; 2020; 11():569760. PubMed ID: 33362758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19.
    Majumder J; Minko T
    AAPS J; 2021 Jan; 23(1):14. PubMed ID: 33400058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Therapeutic Journey of Potential Drugs Against COVID-19.
    Ali F; Hussain S; Zhu YZ
    Mini Rev Med Chem; 2022; 22(14):1876-1894. PubMed ID: 33845740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
    Wooding DJ; Bach H
    Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-SARS-CoV-2 hyperimmune plasma workflow.
    Annamaria P; Eugenia Q; Paolo S
    Transfus Apher Sci; 2020 Oct; 59(5):102850. PubMed ID: 32540345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential therapeutic options for COVID-19: an update on current evidence.
    Niknam Z; Jafari A; Golchin A; Danesh Pouya F; Nemati M; Rezaei-Tavirani M; Rasmi Y
    Eur J Med Res; 2022 Jan; 27(1):6. PubMed ID: 35027080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery.
    Zimmerli A; Monti M; Fenwick C; Eckerle I; Beigelman-Aubry C; Pellaton C; Jaton K; Dumas D; Stamm GM; Infanti L; Andreu-Ullrich H; Germann D; Mean M; Vollenweider P; Stadelmann R; Prella M; Comte D; Guery B; Gachoud D; Rufer N
    Front Immunol; 2021; 12():613502. PubMed ID: 33968017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 Infection of Rhesus Macaques Treated Early with Human COVID-19 Convalescent Plasma.
    Deere JD; Carroll TD; Dutra J; Fritts L; Sammak RL; Yee JL; Olstad KJ; Reader JR; Kistler A; Kamm J; Di Germanio C; Shaan Lakshmanappa Y; Elizaldi SR; Roh JW; Simmons G; Watanabe J; Pollard RE; Usachenko J; Immareddy R; Schmidt BA; O'Connor SL; DeRisi J; Busch MP; Iyer SS; Van Rompay KKA; Hartigan-O'Connor DJ; Miller CJ
    Microbiol Spectr; 2021 Dec; 9(3):e0139721. PubMed ID: 34817208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?
    He X; Zeng XX
    Drug Des Devel Ther; 2022; 16():951-972. PubMed ID: 35386853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19.
    Kumar P; Sah AK; Tripathi G; Kashyap A; Tripathi A; Rao R; Mishra PC; Mallick K; Husain A; Kashyap MK
    Mol Cell Biochem; 2021 Feb; 476(2):553-574. PubMed ID: 33029696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential interventions for novel coronavirus in China: A systematic review.
    Zhang L; Liu Y
    J Med Virol; 2020 May; 92(5):479-490. PubMed ID: 32052466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Coronavirus: A Review from Origin to Current Status of Therapeutic Strategies.
    Hassan M; Zalkifal M; Wahab A; Afzal S; Rafique S; Shahid M; Khan MA; Ahmed N; Idrees M; Shahid AA
    Crit Rev Eukaryot Gene Expr; 2021; 31(3):21-34. PubMed ID: 34369712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.
    Hosseini P; Rahimi H; Najafabadi MM; Ghorbani A; Najafabadi SK; Faridzadeh A; Arabpour J; Khormali E; Deravi N
    Acta Med Indones; 2021 Jan; 53(1):86-95. PubMed ID: 33818411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Antiviral Treatment and Vaccination Strategies Against SARS-CoV-2.
    Bormann M; van de Sand L; Witzke O; Krawczyk A
    Klin Monbl Augenheilkd; 2021 May; 238(5):569-578. PubMed ID: 34020485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.